A detailed history of B. Metzler Seel. Sohn & Co. Ag transactions in Biogen Inc. stock. As of the latest transaction made, B. Metzler Seel. Sohn & Co. Ag holds 7,361 shares of BIIB stock, worth $1.1 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
7,361
Previous 5,861 25.59%
Holding current value
$1.1 Million
Previous $1.36 Million 5.01%
% of portfolio
0.01%
Previous 0.01%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

BUY
$189.07 - $236.8 $283,605 - $355,200
1,500 Added 25.59%
7,361 $1.43 Million
Q2 2024

Aug 13, 2024

BUY
$190.52 - $236.72 $26,863 - $33,377
141 Added 2.47%
5,861 $1.36 Million
Q1 2024

May 15, 2024

SELL
$212.02 - $267.71 $154,562 - $195,160
-729 Reduced 11.3%
5,720 $1.23 Million
Q4 2023

Feb 13, 2024

SELL
$222.59 - $267.94 $489,475 - $589,200
-2,199 Reduced 25.43%
6,449 $1.67 Million
Q3 2023

Nov 13, 2023

BUY
$253.3 - $285.89 $496,468 - $560,344
1,960 Added 29.31%
8,648 $2.22 Million
Q2 2023

Aug 11, 2023

BUY
$275.25 - $318.06 $10,459 - $12,086
38 Added 0.57%
6,688 $1.91 Million
Q1 2023

May 10, 2023

SELL
$256.56 - $292.34 $278,624 - $317,481
-1,086 Reduced 14.04%
6,650 $1.85 Million
Q4 2022

Feb 13, 2023

BUY
$252.44 - $306.72 $201,194 - $244,455
797 Added 11.49%
7,736 $2.14 Million
Q3 2022

Nov 14, 2022

SELL
$194.69 - $268.46 $722,105 - $995,718
-3,709 Reduced 34.83%
6,939 $1.85 Million
Q2 2022

Aug 12, 2022

SELL
$187.54 - $223.02 $24,567 - $29,215
-131 Reduced 1.22%
10,648 $2.17 Million
Q1 2022

May 10, 2022

BUY
$193.77 - $244.14 $113,161 - $142,577
584 Added 5.73%
10,779 $2.27 Million
Q4 2021

Feb 11, 2022

BUY
$223.92 - $287.77 $2.28 Million - $2.93 Million
10,195 New
10,195 $2.45 Million

Others Institutions Holding BIIB

About BIOGEN INC.


  • Ticker BIIB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 144,000,992
  • Market Cap $21.5B
  • Description
  • Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...
More about BIIB
Track This Portfolio

Track B. Metzler Seel. Sohn & Co. Ag Portfolio

Follow B. Metzler Seel. Sohn & Co. Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of B. Metzler Seel. Sohn & Co. Ag, based on Form 13F filings with the SEC.

News

Stay updated on B. Metzler Seel. Sohn & Co. Ag with notifications on news.